Treatment with Akeega plus prednisone and androgen deprivation therapy (ADT) significantly reduced the risk of radiographic progression or death by 54% compared to placebo/abiraterone acetate plus ...
Johnson & Johnson (NYSE:JNJ) on Thursday shared topline data from the Phase 2a DAISY proof-of-concept study evaluating the combination of nipocalimab with an anti-tumor necrosis factor alpha ...
Results from the Phase 3 AMPLITUDE study show the potential of AKEEGA ® (niraparib and abiraterone acetate dual-action tablet) to delay cancer progression and worsening of symptoms Data show a nearly ...
Johnson & Johnson announced that Health Canada has issued a Notice of Compliance for Lazcluze in combination with Rybrevant for the first-line treatment of adult patients with locally advanced or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results